美国VaxInnate www.vaxinnate.com
VaxInnate公司是一家私人持有的生物技术公司，开发新颖，专有疫苗为大流行病和季节性流感。该公司的突破疫苗是基于其Toll样受体（ TLR为）的技术平台，大大提高了疫苗的免疫原性和有效性。利用TLR为技术，疫苗可产生的简单，低成本，高可扩展性重组DNA技术，避免许多挑战和隐患的鸡蛋或细胞培养流感疫苗的生产。 VaxInnate的技术有可能显着提高成本效益，制造能力和效力的流感疫苗-面临的关键问题的临床和公共健康的社区。

美国生物制药公司VaxInnate总裁艾伦·肖在接受新华社记者采访时表示，针对这种新型病毒(猪流感病毒)的疫苗样品有望在4周内研制成功。
VaxInnate is a privately-held biotechnology company developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company's breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy. Using the TLR technology, vaccines can be produced by simple, low-cost, highly-scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture influenza vaccine production. VaxInnate's technology has the potential to significantly improve the cost-effectiveness, manufacturing capacity, and potency of influenza vaccines - key issues facing the clinical and public health communities.

VaxInnate has a BSL2+ laboratory operational within the Cranbury site, and also has access to BSL-2 vivarium space through a collaborative research agreement with Yale University . VaxInnate also has a collaborative arrangement with an academic institution for access to high level biocontainment facilities (BSL-3 and -4). Since avian influenza requires BSL-3 or -4 facilities, depending on the strain in question, this access enables the VaxInnate to conduct live virus challenges in animal models.